Back to results
US 2008/0306008 A1Published application
Peptides for Use in the Treatment of Obesity
AssigneeNova Nordisk A/S
InventorsUlrich Sensfuss, Leif Christensen
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
Claims59
A compound of formula Ia, Ib or Ic:
- R1—S-Z1-Z2-Z3-c[X1-X2-X3-Arg-X4-X5]N(R′)2 [Ia]
- R1—S-Z2-Z3-c[X1-X2-X3-Arg-X4-X5]N(R′)2 [Ib]
- R1—S-Z1-c[X1-X2-X3-Arg-X4-X5]N(R′)2 [Ic]
- wherein R1 represents a straight-chain, branched and/or cyclic C14-20alkanoyl, C14-20alkenoyl or C14-20alkynoyl which may optionally be substituted with one or more substituents selected from halogen, hydroxyl and aryl, or R1 represents C9-17—C(O)—NH—S(O)2—(CH2)3—C(O)—;
- S represents a glycolether-based structure according to one of the formulas IIa-IIe
- Z1 and Z2 independently represent Gly, Ser, Thr, Gln, Asn, His, homoArg, Arg, Lys, Dab, Dap or Orn;
- Z3 represents Ala, Val, Leu, Ile, Met or Nle;
- X1 represents Glu, Asp, Cys, homoCys, Pen, Lys, Orn, Dab or Dap;
- X2 represents His, Cit, Dab, Dap, Cgl, Cha, Val, Ile, tBuGly, Leu, Tyr, Glu, Ala, Nle, Met, Met(O), Met(O2), Gln, Gln(alkyl), Gln(aryl), Asn, Asn(alkyl), Asn(aryl), Ser, Thr, Cys, Pro, Hyp, Tic, 2-PyAla, 3-PyAla, 4-PyAla, (2-thienyl)alanine, 3-(thienyl)alanine, (4-thiazolyl)Ala, (2-furyl)alanine, (3-furyl)alanine or Phe, wherein the phenyl moiety of said Phe is optionally substituted with a substituent selected among halogen, hydroxy, alkoxy, nitro, benzoyl, methyl, trifluoromethyl, amino and cyano;
- X3 represents D-Phe, wherein the phenyl moiety in D-Phe may optionally be substituted with one or more substituents selected among halogen, hydroxy, alkoxy, nitro, methyl, trifluoromethyl and cyano;
- X4 represents Trp, 2-NaI, a (3-benzo[b]thienyl)alanine residue or a (S)-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid residue;
- X5 represents Glu, Asp, Cys, homoCys, Pen, Lys, Om, Dab or Dap;
- wherein X1 and X5 are joined, rendering the compound of formula Ia, Ib or Ic cyclic, either via a disulfide bridge deriving from X1 and X5 both independently being Cys, homoCys or Pen, or via an amide bond formed between a carboxylic acid in the side-chain of X1 and an amino group in the side chain of X5, or between a carboxylic acid in the side-chain of X5 and an amino group in the side-chain of X1;
- each R′ independently represents hydrogen or C1-6alkyl, which may optionally be substituted with one or more amino or hydroxy;
- with the proviso that the compound of formula Ia, Ib or Ic is not
- 2-[2-(octadecanoylamino)ethoxy]ethoxyacetyl-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
- 3-(2-{2-[2-(2-(hexadecanoylamino)ethoxy)ethoxy]ethoxy}ethoxy)propionyl-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
- 2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-His-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2,
- 2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-Arg-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2 or
- 2-[2-(hexadecanoylamino)ethoxy]ethoxyacetyl-Gln-Ser-Nle-c[Glu-Hyp-D-Phe-Arg-Trp-Lys]-NH2;
- and pharmaceutically acceptable salts, prodrugs and solvates thereof.
18 more elements
(canceled)
(canceled)
Dependencies are inferred from the claim text.